• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ACELYRIN, INC. - Common Stock (NQ:SLRN)

    2.250 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.250
    Bid (Size) 1.900 (1)
    Ask (Size) 3.040 (7)
    Prev. Close 2.250
    Today's Range 2.250 - 2.250
    52wk Range 1.845 - 7.250
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Alumis and ACELYRIN Announce Amended Merger Agreement
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
    From Kahn Swick & Foti, LLC
    Via Business Wire

    Performance

    YTD
    -31.8%
    -31.8%
    1 Month
    -14.8%
    -14.8%
    3 Month
    +11.4%
    +11.4%
    6 Month
    -63.5%
    -63.5%
    1 Year
    -51.1%
    -51.1%

    More News

    Read More
    3 Biopharmaceutical Stocks Bucking the Sell-Off
    Via MarketBeat
    Topics World Trade
    Exposures Product Safety Tariff
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
    From ACELYRIN, INC.
    Via GlobeNewswire
    Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
    Via Stocktwits
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    These stocks are moving in today's pre-market session
    Via Chartmill
    ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
    From ACELYRIN, INC.
    Via GlobeNewswire
    Wondering what's happening in today's after-hours session?
    Via Chartmill
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, SLRN, PTMN, HEES on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PLYA, SLRN, NVRO, AMPS on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
    From Kahn Swick & Foti, LLC
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, TGI, PTMN on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
    From Ademi & Fruchter LLP
    Via Business Wire
    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
    From ACELYRIN, INC.
    Via GlobeNewswire
    Nasdaq Down 1.5%; RPM Posts Upbeat Results
    Via Benzinga
    Dow Surges Over 100 Points; US Trade Deficit Widens In November
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
    From ACELYRIN, INC.
    Via GlobeNewswire
    What's Going On With ACELYRIN Shares Friday?
    Via Benzinga

    Frequently Asked Questions

    Is ACELYRIN, INC. - Common Stock publicly traded?
    Yes, ACELYRIN, INC. - Common Stock is publicly traded.
    What exchange does ACELYRIN, INC. - Common Stock trade on?
    ACELYRIN, INC. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ACELYRIN, INC. - Common Stock?
    The ticker symbol for ACELYRIN, INC. - Common Stock is SLRN on the Nasdaq Stock Market
    What is the current price of ACELYRIN, INC. - Common Stock?
    The current price of ACELYRIN, INC. - Common Stock is 2.250
    When was ACELYRIN, INC. - Common Stock last traded?
    The last trade of ACELYRIN, INC. - Common Stock was at 04/23/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.